In vivo bidirectional modulatory effect of benzodiazepine receptor ligands on GABAergic transmission evaluated by positron emission tomography in non-human primates
The DOI matches its Crossref record; 66 of the 72 references it cites were found in a registry or an index.
Abstract
The central type benzodiazepine receptor (BDZr), an allosteric modulatory site of the GABAA receptor-anion channel, has been shown in vitro to respond to drugs with positive efficacy (agonists), zero efficacy (competitive antagonists) and drugs with negative efficacy (inverse agonists). However, this general concept of the function of BDZr drugs has rarely been assessed in intact living brain. We report here in on a non-invasive in vivo assessment of the intrinsic efficacies of BDZr drugs in the brain of non-human primates. We have performed an in vivo simultaneous determination of fractional BDZr occupancy and the resulting pharmacological efficacies of the full agonist diazepam, the partial agonist bretazenil, the antagonist flumazenil (Ro15-1788), the partial inverse agonist Ro15-4513 and the full inverse agonist methyl beta-carboline-3-carboxylate (beta-CCM). Positron emission tomography (PET) was used to estimate fractional BDZr occupancy measured as the in vivo displacement in the brain of the positron emitter radioligand, [11C]flumazenil. Simultaneously, the proconvulsant or anticonvulsant efficacies of the BDZr drugs were measured as their abilities to facilitate or counteract the central effects of an infusion of pentylenetetrazol, a non-competitive GABA antagonist acting on the picrotoxin site of the receptor complex. This was measured using electroencephalographic recording (EEG). Our results show that, in vivo, the fractional receptor occupancy by a given drug is perfectly correlated with its resulting graded pharmacological effects, as predicted from the competitive drug receptor interaction theory. Furthermore, the slope of the relationship between fractional receptor occupancies and the resulting pharmacological effects (an index of intrinsic efficacy) strictly depends on the BDZr ligand considered. Diazepam displayed a strong positive intrinsic efficacy, and, in contrast, beta-CCM a marked negative one. Between these two extremes, the partially active drugs bretazenil and Ro15-4513, which required a large fractional receptor occupancy to produce significant anti- or proconvulsant effects, respectively, displayed only a weak intrinsic efficacy. Flumazenil did not produce any significant pharmacological effect. We observed that the in vivo intrinsic efficacies of diazepam, flumazenil and beta-CCM correlate with their intrinsic efficacies as measured by their modulatory effects on the GABA-dependent membrane chloride conductance in vitro. Thus, the intrinsic efficacies measured using PET and EEG are likely to reflect the different in vivo abilities of BDZr drugs to induce or stabilize the GABAA-benzodiazepine chloride channel in a given conformation.(ABSTRACT TRUNCATED AT 400 WORDS)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, decreasing medication by constant amounts (linear tapering) tends to cause increasingly severe side effects 47,50,51 .”
From Tapering of SSRI treatment to mitigate withdrawal symptoms (2019) · cites this paper as [51]
In the citing paper
“Withdrawal regimes for benzodiazepines recommend dosage reductions that are proportional to the current dose (most commonly suggesting 10% reductions), yielding exponentially decreasing regimes, as opposed to linear reductions 47,51,53 (Figure 2b).”
From Tapering of SSRI treatment to mitigate withdrawal symptoms (2019) · cites this paper as [51]
In the citing paper
“The shape of the relationship between dose of benzodiazepine and activity at gamma-aminobutyric acid-A (GABA-A) receptors is hyperbolic: steeply inclining at low doses, flattening at higher doses.”
From Pharmacological principles for safe benzodiazepine and Z-drug dose reduction (2026) · cites this paper as Brouillet et al., 1991
In the citing paper
“This table, based on the E max equation of best fit derived from the data in Brouillet et al. (1991), after conversion to human equivalent dosage (Nair & Jacob, 2016), allows transformation from dosage of diazepam to indicator of biological effect, based on percentage occupancy of GABA-A”
From Pharmacological principles for safe benzodiazepine and Z-drug dose reduction (2026) · cites this paper as Brouillet et al., 1991
In the citing paper
“PET scanning, using the radioligand [11C]flumazenil in non-human primates (Figure 2a), allows visualization of this hyperbolic relationship (Atkins & Nimmo, 1975; Brouillet et al., 1991; Holford, 2018).”
From Pharmacological principles for safe benzodiazepine and Z-drug dose reduction (2026) · cites this paper as Brouillet et al., 1991
Citations
Cites
Benzodiazepine Receptor: Demonstration in the Central Nervous System
Möhler, H., & Okada, T. (1977) · Science · doi:10.1126/science.918669 · Cited by 1,700
Specific benzodiazepine receptors in rat brain characterized by high-affinity (3H)diazepam binding
Braestrup, C., & Squires, R. F. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.9.3805 · Cited by 1,264
Selective antagonists of benzodiazepines
Hunkeler, W., Möhler, H., Pieri, L., Polc, P., Bonetti, E. P., Cumin, R., Schaffner, R., & Haefely, W. (1981) · Nature · doi:10.1038/290514a0 · Cited by 1,232
Quantitative Analysis of D2 Dopamine Receptor Binding in the Living Human Brain by PET
Farde, L., Hall, H., Ehrin, E., & Sedvall, G. (1986) · Science · doi:10.1126/science.2867601 · Cited by 831
Type I and Type II GABA A -Benzodiazepine Receptors Produced in Transfected Cells
Pritchett, D. B., Lüddens, H., & Seeburg, P. H. (1989) · Science · doi:10.1126/science.2551039 · Cited by 717
Structural and functional basis for GABAA receptor heterogeneity
Levitan, E. S., Schofield, P. R., Burt, D. R., Rhee, L. M., Wisden, W., Köhler, M., Fujita, N., Rodriguez, H. F., Stephenson, A., Darlison, M. G., et al. (1988) · Nature · doi:10.1038/335076a0 · Cited by 589
Squires, R. F., Casida, J. E., Richardson, M., & Saederup, E. (1983) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)14273-9 · Cited by 551
Interaction of Convulsive Ligands with Benzodiazepine Receptors
Braestrup, C., Schmiechen, R., Neef, G., Nielsen, M., & Petersen, E. N. (1982) · Science · doi:10.1126/science.6281892 · Cited by 547
A Selective Imidazobenzodiazepine Antagonist of Ethanol in the Rat
Suzdak, P. D., Glowa, J. R., Crawley, J. N., Schwartz, R. D., Skolnick, P., & Paul, S. M. (1986) · Science · doi:10.1126/science.3022383 · Cited by 543
Cerebellar GABAA receptor selective for a behavioural alcohol antagonist
Lüddens, H., Pritchett, D. B., Köhler, M., Killisch, I., Keinänen, K., Monyer, H., Sprengel, R., & Seeburg, P. H. (1990) · Nature · doi:10.1038/346648a0 · Cited by 538
Research works printed but not linked: 5
- Bonnetti, 1985, The partial inverse benzodiazepine agonist Ro15-4513 antagonizes acute ethanol effects in mice and rats, Br. J. Pharmacol., 86, 463P
- Frey, 1988, Muscarinic receptors imaging in human brain using [11C]scopolamine and positron emission tomography, J. Nucl. Med., 29, 808
- Furchgott, 1966, The use of β-haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes, Adv. Drug. Res., 3, 21
- Haefely, 1985, Recent advances in molecular pharmacology of benzodiazepine receptors and in the structure-activity relationships of their agonists and antagonists, Vol. 14, 165
- Mazière, 1983, 11C-Ro15-1788 et11C-Flunitrazepam, deux coordinats pour l'etude par tomographie par positons des sites de liaison des benzodiazepines, C.R. Acad. Sci., 296, 871
Cited by
Tapering of SSRI treatment to mitigate withdrawal symptoms
Horowitz, M. A., & Taylor, D. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30032-x · Cited by 280
Pike, V. W., Halldin, C., Crouzel, C., Barré, L., Nutt, D., Osman, S., Shah, F., Turton, D. R., & Waters, S. L. (1993) · Nuclear Medicine and Biology · doi:10.1016/0969-8051(93)90082-6 · Cited by 139
Target site occupancy: Emerging generalizations from clinical and preclinical studies
Grimwood, S., & Hartig, P. R. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.03.002 · Cited by 139
Yanai, K., Ryu, J. H., Watanabe, T., Iwata, R., Ido, T., Sawai, Y., Ito, K., & Itoh, M. (1995) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1995.tb16386.x · Cited by 110
Criswell, H. E., & Breese, G. R. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300750 · Cited by 118
GABAA Receptor α2/α3 Subtype-Selective Modulators as Potential Nonsedating Anxiolytics
Atack, J. R. (2009) · Current topics in behavioral neurosciences · doi:10.1007/7854_2009_30 · Cited by 86
Ator, N. A., Atack, J. R., Hargreaves, R. J., Burns, H. D., & Dawson, G. R. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.158303 · Cited by 66
Lamusuo, S., Pitkänen, A., Jutila, L., Ylinen, A., Partanen, K. P. L., Kälviäinen, R. K., Ruottinen, H., Oikonen, V., Någren, K., Lehikoinen, P., et al. (2000) · Neurology · doi:10.1212/wnl.54.12.2252 · Cited by 63
Targeting the Modulation of Neural Circuitry for the Treatment of Anxiety Disorders
Farb, D. H., & Ratner, M. H. (2014) · Pharmacological Reviews · doi:10.1124/pr.114.009126 · Cited by 55
Discontinuation of psychotropic medication: a synthesis of evidence across medication classes.
Vinkers, C. H., Kupka, R. W., Penninx, B. W., Ruhé, H. G., van Gaalen, J. M., van Haaren, P. C. F., Schellekens, A. F. A., Jauhar, S., Ramos-Quiroga, J. A., Vieta, E., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02445-4 · Cited by 51
Malizia, A. L., Gunn, R. N., Wilson, S. J., Waters, S., Bloomfield, P. M., Cunningham, V. J., & Nutt, D. (1996) · Neuropharmacology · doi:10.1016/s0028-3908(96)00072-x · Cited by 42
Klimas, M. T. (2002) · Molecular Imaging and Biology · doi:10.1016/s1536-1632(02)00017-3 · Cited by 42
Partial limbic kindling—Brain, behavior, and the benzodiazepine receptor
Adamec, R. E. (1993) · Physiology & Behavior · doi:10.1016/0031-9384(93)90247-d · Cited by 31
Analysis of Dynamic Radioligand Displacement or “Activation” Studies
Friston, K. J., Malizia, A. L., Wilson, S., Cunningham, V. J., Jones, T., & Nutt, D. (1997) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199701000-00011 · Cited by 29
Selective labelling of diazepam‐insensitive GABA A receptors in vivo using [ 3 H]Ro 15‐4513
Pym, L. J., Cook, S. M., Rosahl, T. W., McKernan, R. M., & Atack, J. R. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706392 · Cited by 26
1,4-Benzodiazepine derivatives as anticonvulsant agents in DBA/2 mice
Sarro, G. D., Gitto, R., Rizzo, M., Zappia, M., & Sarro, A. D. (1996) · General Pharmacology The Vascular System · doi:10.1016/0306-3623(95)02147-7 · Cited by 19
Psychopharmacology -- in vivo neurochemistry and pharmacology
Grasby, P. M., Malizia, A. L., & Bench, C. J. (1996) · British Medical Bulletin · doi:10.1093/oxfordjournals.bmb.a011564 · Cited by 19
Bottlaender, M., Brouillet, E., Varastet, M., Le Breton, C., Schmid, L., Fuseau, C., Sitbon, R., Crouzel, C., & Mazière, M. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.62031102.x · Cited by 17
Self-citationBehavioral effects of flumazenil in the social conflict test in mice
Uhlířová, L., Šustková-Fišerová, M., & Kršiak, M. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1583-y · Cited by 18
Benzodiazepine receptors and positron emission tomography: ten years of experience. A new beginning?
Malizia, A. L., & Richardson, M. P. (1995) · Journal of Psychopharmacology · doi:10.1177/026988119500900411 · Cited by 16
Atack, J. R., Eng, W., Gibson, R. E., Ryan, C. N., Francis, B. E., Sohal, B., Dawson, G. R., Hargreaves, R. J., & Burns, H. D. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00216.x · Cited by 15
Atack, J. R., Scott‐Stevens, P., Beech, J. S., Fryer, T. D., Hughes, J. L., Cleij, M. C., Baron, J., Clark, J. C., Hargreaves, R. J., & Aigbirhio, F. I. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.114884 · Cited by 15
Sarro, G. D., Carotti, A., Campagna, F., Mckernan, R., Rizzo, M., Falconi, U., Palluotto, F., Giusti, P., Rettore, C., & Sarro, A. D. (2000) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(99)00230-0 · Cited by 14
Sarro, G. D., Chimirri, A., McKernan, R. M., Quirk, K., Giusti, P., & Sarro, A. D. (1997) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(96)00565-5 · Cited by 12
The Service Hospitalier Frédéric Joliot – contributions to PET chemistry over the years
Roeda, D., Kühnast, B., Hammadi, A., & Dollé, F. (2007) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.1420 · Cited by 10
Pasqua, O. E. D., Kruk, M. R., Hamstra, R., Voskuyl, R. A., & Danhof, M. (1998) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702155 · Cited by 10
Depression and Anxiety Disorders
Karamustafalıoğlu, O., & Yumrukçal, H. (2025) · Wiley eBooks · doi:10.1002/9781119870203.mpg003.pub2 · Cited by 8
Sarro, G. D., Chimirri, A., Zappalà, M., Guisti, P., Lipartiti, M., & Sarro, A. D. (1996) · General Pharmacology The Vascular System · doi:10.1016/s0306-3623(96)00049-3 · Cited by 6
Auvity, S., Vodovar, D., Goutal, S., Cisternino, S., Chevillard, L., Soyer, A., Bottlaender, M., Caillé, F., Mégarbane, B., & Tournier, N. (2023) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x231221040 · Cited by 5
Self-citationBottlaender, M., Schmid, L., Fuseau, C., Fournier, D., Brouillet, E., & Mazière, M. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)00004-6 · Cited by 5
Self-citationCamp, N. V., Bramoullé, Y., & Hantraye, P. (2011) · Neuromethods · doi:10.1007/978-1-61779-298-4_9 · Cited by 4
Self-citationBrown, O., McLay, L., Glue, P., & Barak, Y. (2025) · Journal of the Academy of Consultation-Liaison Psychiatry · doi:10.1016/j.jaclp.2025.06.007 · Cited by 3
Chavoix, C., Brouillet, E., Hantraye, P., Sayette, V. D. L., Kunimoto, M., Varastet, M., Guibert, B., Dodd, R. H., Fournier, D., Naquet, R., et al. (1992) · Elsevier eBooks · doi:10.1016/b978-0-444-89710-7.50049-5 · Cited by 2
Self-citationDepression and Anxiety Disorders
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg003 · Cited by 1
Pharmacological principles for safe benzodiazepine and Z-drug dose reduction
Horowitz, M., Lamberson, N., Brandt, J., Framer, A., Shapiro, B., Sørensen, A., Cadogan, C., Ritvo, A., & Taylor, D. (2026) · Psychological Medicine · doi:10.1017/s0033291726104887
“This table, based on the E max equation of best fit derived from the data in Brouillet et al. (1991), after conversion to human equivalent dosage (Nair & Jacob, 2016”
Title Page Reducing Abuse Liability of GABAA/Benzodiazepine Ligands via Selective Partial-Agonist
Ator, N. A., Atack, J. R., Hargreaves, R. J., Burns, H. D., Dawson, G. R., & Sharp, M. (2009)
Safe Deprescribing of Benzodiazepines and Z‐drugs
(2024) · Wiley eBooks · doi:10.1002/9781394291052.mdg003
Metadata
- Authors
- Brouillet, E., Chavoix, C., Bottlaender, M., Khalili-Varasteh, M., Hantraye, P., Fournier, D., Dodd, R. H., & Mazière, M.
- Corresponding author
- Mazière, Mariannick
- Venue
- Brain Research
- Publisher
- Elsevier BV
- Published
- 1991-08
- Volume
- 557
- Issue
- 1-2
- Pages
- 167-176
- ISSN
- 0006-8993 (ISSN-L)
- OpenAlex
- W2051214011
- Cited by
- 37
- References
- 72
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 2 · 2023: 1 · 2021: 1 · 2019: 1 · 2014: 1
- FWCI
- 0.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Brain Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Fondation de l'Avenir pour la Recherche Médicale Appliquée
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Keywords
- benzodiazepine receptor, GABAergic neurotransmission, GABAA receptor, inverse agonists, partial agonists, intrinsic efficacy, receptor occupancy, diazepam, flumazenil, Ro 15-4513, bretazenil, pentylenetetrazole, anticonvulsant activity, proconvulsant effects, non-human primates, 11C-flumazenil PET, EEG, allosteric modulation, benzodiazepine antagonists, benzodiazepine receptor agonists
- MeSH terms
- Animals, Azides, Benzodiazepines, Benzodiazepinones, Binding, Competitive, Carbolines, Cerebral Cortex, Diazepam, Electroencephalography, Flumazenil, gamma-Aminobutyric Acid, Ligands, Male, Synaptic Transmission, Papio, Pentylenetetrazole, Receptors, GABA-A, Seizures, Tomography, Emission-Computed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.